MEDP vs SYRE
Medpace vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
VS
SYRE
Spyre Therapeutics, Inc.
68
Buy
| Metric | MEDP | SYRE |
|---|
| AI Score |
64
|
68
|
| Price |
$596.78
|
$104.13
|
| P/E Ratio |
34.82×
|
-52.69×
|
| ROE |
98.3%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
28.8%
|
0.0%
|
| Debt / Equity |
0.28×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
72.1
|
53.3
|
| Beta |
1.151
|
3.026
|
| Expected Upside |
+3.0%
|
—
|
AI Committee View
Current Innellis committee reasoning for MEDP versus SYRE.
SYRE leads by 4 points.
SYRE scores 68/100 (Buy) versus MEDP at 64/100 (Buy).
MEDP Committee View
67% agreement
6 analysts
The primary driver is eps growing 26.8% yoy. The main limiting factor is p/e of 34.2 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 110.1% shows genuine earnings power backing the valuation — Value
- EPS growing 26.8% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 34.2 is moderate-to-rich — Value
- Price-to-book of 34.5x prices in significant intangible value — Value
- RSI at 72 is in overbought territory — Technical
SYRE Committee View
83% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical